THU0236 Once-Daily Dosing of GLPG0634, a Selective JAK1 Inhibitor, is Supported by Its Active Metabolite

Abstract

BackgroundGLPG0634 is an orally-available, selective, inhibitor of Janus kinase 1 (JAK1). Through inhibition of signaling pathways for cytokines involved in rheumatoid arthritis (RA), non-selective JAK inhibitors have shown long-term efficacy...